WO2007143631A3 - Nutraceutical treatments for diabetic and non-diabetic wound healing - Google Patents

Nutraceutical treatments for diabetic and non-diabetic wound healing Download PDF

Info

Publication number
WO2007143631A3
WO2007143631A3 PCT/US2007/070368 US2007070368W WO2007143631A3 WO 2007143631 A3 WO2007143631 A3 WO 2007143631A3 US 2007070368 W US2007070368 W US 2007070368W WO 2007143631 A3 WO2007143631 A3 WO 2007143631A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic
wound healing
resveratrol
chlorophyll
arginine
Prior art date
Application number
PCT/US2007/070368
Other languages
French (fr)
Other versions
WO2007143631A2 (en
Inventor
Xiaoming Xu Chien
Debasis Bagchi
Original Assignee
Interhealth Nutraceuticals Inc
Xiaoming Xu Chien
Debasis Bagchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/809,149 external-priority patent/US7887848B2/en
Application filed by Interhealth Nutraceuticals Inc, Xiaoming Xu Chien, Debasis Bagchi filed Critical Interhealth Nutraceuticals Inc
Priority to US12/303,033 priority Critical patent/US20100062087A1/en
Publication of WO2007143631A2 publication Critical patent/WO2007143631A2/en
Publication of WO2007143631A3 publication Critical patent/WO2007143631A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

In an embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, traws-resveratrol, /-arginine, chlorophyll, vitamin C and aloe vera combined synergistically to reduce inflammation in mammals suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, fr-απs-resveratrol, /-arginine, chlorophyll, vitamin C and aloe vera combined synergistically to enhance wound healing in mammals suffering from diabetes. In an alternative embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, trans-resveratrol, /-arginine, chlorophyll, vitamin C and aloe vera combined synergistically to reduce inflammation in mammals not suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, trαns-resveratrol, /-arginine, chlorophyll, vitamin C and aloe vera, combined synergistically to enhance wound healing in mammals not suffering from diabetes.
PCT/US2007/070368 2006-06-02 2007-06-04 Nutraceutical treatments for diabetic and non-diabetic wound healing WO2007143631A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/303,033 US20100062087A1 (en) 2006-06-02 2007-06-04 Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81074106P 2006-06-02 2006-06-02
US60/810,741 2006-06-02
US11/809,149 US7887848B2 (en) 2006-05-31 2007-05-31 Nutraceutical treatments for diabetic and non-diabetic wound healing
US11/809,149 2007-05-31

Publications (2)

Publication Number Publication Date
WO2007143631A2 WO2007143631A2 (en) 2007-12-13
WO2007143631A3 true WO2007143631A3 (en) 2008-01-24

Family

ID=38802292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/070368 WO2007143631A2 (en) 2006-06-02 2007-06-04 Nutraceutical treatments for diabetic and non-diabetic wound healing

Country Status (1)

Country Link
WO (1) WO2007143631A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887848B2 (en) 2006-05-31 2011-02-15 Interhealth Nutraceuticals, Inc. Nutraceutical treatments for diabetic and non-diabetic wound healing
DE102007030931A1 (en) * 2007-07-03 2009-01-08 Birgit Riesinger Composition containing at least one nutritive, at least one disinfecting or decontaminating and / or at least one protease inhibiting active substance and / or active substance complex
WO2011048617A2 (en) * 2009-10-19 2011-04-28 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
IT1402749B1 (en) * 2010-10-28 2013-09-18 Indena Spa COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ULCERS OF VARIOUS ORIGIN
US20150005391A1 (en) * 2013-06-26 2015-01-01 COLE Research & Design, Inc. Method of reducing scarring
JP5788065B2 (en) 2013-07-14 2015-09-30 アシロス・エ／エス New bioactive alkaloids and alkaloid fractions derivable from Ribes species
US10099995B2 (en) 2015-12-24 2018-10-16 Cole Research and Design, LLC Resveratrol esters

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5972999A (en) * 1997-01-22 1999-10-26 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5976568A (en) * 1997-02-21 1999-11-02 Medical Doctors' Research Institute, Inc. Modular system of dietary supplement compositions for optimizing health benefits and methods
US5976548A (en) * 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
US6048903A (en) * 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US20020155138A1 (en) * 2001-01-19 2002-10-24 Martin Katharine M. Composition containing Hedychium extract and use thereof
US20030026855A1 (en) * 1998-09-09 2003-02-06 Kameneva Marina V. Artificial blood fluids and microflow drag reducing factors for enhanced blood circulation
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
US20050196359A1 (en) * 2004-03-03 2005-09-08 D'amelio Frank S.Sr. Method and composition for treating oral bacteria and inflammation
US6953595B2 (en) * 2000-06-16 2005-10-11 Robert Basic Inhibitors of apoptosis of nerve cells
US20060009099A1 (en) * 2004-07-12 2006-01-12 Closure Medical Corporation Adhesive-containing wound closure device and method
US20060024383A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses
US20060039937A1 (en) * 2003-10-31 2006-02-23 Teresa Mujica-Fernaudd Composition having antioxidant properties
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048903A (en) * 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5976548A (en) * 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
US5972999A (en) * 1997-01-22 1999-10-26 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5976568A (en) * 1997-02-21 1999-11-02 Medical Doctors' Research Institute, Inc. Modular system of dietary supplement compositions for optimizing health benefits and methods
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
US20030026855A1 (en) * 1998-09-09 2003-02-06 Kameneva Marina V. Artificial blood fluids and microflow drag reducing factors for enhanced blood circulation
US6953595B2 (en) * 2000-06-16 2005-10-11 Robert Basic Inhibitors of apoptosis of nerve cells
US20020155138A1 (en) * 2001-01-19 2002-10-24 Martin Katharine M. Composition containing Hedychium extract and use thereof
US20060039937A1 (en) * 2003-10-31 2006-02-23 Teresa Mujica-Fernaudd Composition having antioxidant properties
US20050196359A1 (en) * 2004-03-03 2005-09-08 D'amelio Frank S.Sr. Method and composition for treating oral bacteria and inflammation
US20060009099A1 (en) * 2004-07-12 2006-01-12 Closure Medical Corporation Adhesive-containing wound closure device and method
US20060024383A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ALBINA ET AL.: "Temporal expression of different pathways of 1-arginine metabolism in healing wounds", J. IMMUNOL., vol. 144, no. 10, 15 May 1990 (1990-05-15), pages 3877 - 3880 *
BABU ET AL.: "Estimation of trans-resveratrol in herbal extracts and dosage forms by high-performance thin-layer chromatography", CHEM. PHARM. BULL (TOKYO), vol. 53, no. 6, June 2005 (2005-06-01), pages 691 - 693 *
BAGCHI ET AL.: "Angiogenic and anti-angiogenic properties of natural polyphenolic antioxidants", IFT ANNUAL MEETING-CHICAGO SESSION 32, ANGIOGENESIS AND FUNCTIONAL FOODS, 2003 *
BARRELL ET AL.: "Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome", LANCET, vol. 346, no. 8988, 2 December 1995 (1995-12-02), pages 1458 - 1463 *
BRETT ET AL.: "Chlorophyllin - A Healer? A Hypothesis for its Activity", WOUNDS, vol. 17, no. 7, 2005, pages 190 - 1901 *
BURNS ET AL.: "Plant Foods and Herbal Sources of Resveratrol", J. AGRIC. FOOD CHEM., vol. 50, no. 11, 26 April 2002 (2002-04-26), pages 3337 - 3340 *
CHEN ET AL.: "Synthesis and Anti-inflammatory Activity of Resveratrol Analogs", CHEM. PHARM. BULL., vol. 53, no. 12, 14 September 2005 (2005-09-14), pages 1587 - 1590 *
EGNER ET AL.: "Chlorophylin intervention reduces aflatoxin DNA adducts in individuals at high risk for liver cancer", PNAS, vol. 98, no. 25, 4 December 2001 (2001-12-04), pages 14601 - 14606 *
GOOVA ET AL.: "Blockade of Receptor for Advanced Glycation End-Products Restores Effective Wound Healing in Diabetic Mice", AM. JOURNAL OF PATHOLOGY, vol. 159, no. 2, August 2001 (2001-08-01), pages 1 *
HEGGERS ET AL.: "Effect of the combination of Aloe vera, nitroglycerin, and L-NAME on wound healing in the rat excisional model", J. ALTERN. COMPLEMENT MED., vol. 3, no. 2, 1997, pages 149 - 153 *
KHANNA ET AL.: "Dermal wound healing properties of redox-active grape seed proanthocyanidins", FREE RADICAL BIOLOGY & MEDICINE, vol. 33, no. 8, 20 June 2002 (2002-06-20), pages 1089 - 1096 *
NG ET AL.: "Plants Beneficial to the Aging Brain", NEUROEMBRYOL AGING, vol. 3, 24 April 2006 (2006-04-24), pages 136 - 141 *
PICKUP ET AL.: "Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes", DIABETES CARE, vol. 27, 2004, pages 813 - 823 *
WALLER ET AL.: "A chemical investigation of Aloe barbadensis miller", PROC. OKLA. ACAD. SCI., vol. 58, 1978, pages 69 - 76 *

Also Published As

Publication number Publication date
WO2007143631A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
WO2007143002A3 (en) Nutraceutical treatments for diabetic and non-diabetic wound healing
WO2007143631A3 (en) Nutraceutical treatments for diabetic and non-diabetic wound healing
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010070675A3 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
NZ589228A (en) Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) for the treatment of a brain tumour
WO2008156869A3 (en) Sirtuin modulating thiazolopyridine compounds
WO2010102192A3 (en) Non-steroidal anti-inflammatory ophthalmic compositions
WO2002096221A3 (en) Skin diet
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2011060206A3 (en) Material and methods for treating or preventing her-3 associated diseases
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MY148496A (en) Dpp iv inhibitor formulations
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2009147201A3 (en) Anti-inflammatory agents
WO2008047061A3 (en) Cosmetic oral and/or parenteral use of glucosamine optionally in combination with at least one polyphenol compound, and corresponding composition
WO2011061252A3 (en) Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder
WO2011001111A3 (en) Use of jasmonic acid to treat oily skin
WO2010119102A3 (en) Pharmaceutical composition containing proton pump inhibitor for treating dermatological autoimmune diseases
WO2008012107A3 (en) Use of polyethylene glycol in inflammatory skin conditions and wound healing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798090

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07798090

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12303033

Country of ref document: US